Leading Microbiome Researcher Dr. Eric Pamer Joins Diversigen’s Scientific Advisory Board
25 January 2021 - 10:00PM
Diversigen, Inc., a subsidiary of OraSure Technologies Inc.
(NASDAQ: OSUR), today announced that Eric Pamer, M.D., Professor of
Medicine, Section of Infectious Diseases and Global Health and
director of the Duchossois Family Institute at the University of
Chicago, has joined its scientific advisory board. Dr. Pamer is an
internationally recognized physician and scientist in the
microbiome field. His research focuses on the role of the
microbiome in immune defense and disease resistance.
“We are thrilled to have Dr. Pamer joining Diversigen’s
scientific advisory board.” said Joy Nassif, Vice President,
Services at Diversigen Inc. “Establishing a world-class scientific
advisory board is just one of many ways Diversigen is bringing the
best minds of academia and industry together to accelerate the
microbiome industry. Dr. Pamer’s guidance and insights will be
invaluable in evolving our multiomics vision.”
“Diversigen has built a world-class microbiome analysis
platform, which has enabled scientists to conduct experiments and
analyses to further the microbiome field," said Dr. Pamer. “I am
very excited to collaborate with the Diversigen team to leverage my
experience and help shape new approaches as they continue to expand
their multiomic solution offerings.”Dr. Pamer joined the University
of Chicago from Memorial Sloan Kettering Cancer Center in New York
City, where he served as head of the Division of Subspecialty
Medicine from 2011 to 2018 and director of the Center for Microbes,
Inflammation and Cancer from 2010 to 2019. Board certified in
internal medicine and infectious diseases, Pamer is a member of the
American Association of Physicians and of the Bill and Melinda
Gates Foundation’s Global Health Scientific Advisory Committee and
a Fellow of the Infectious Diseases Society of America. He has
published more than 200 articles and book chapters.
About Diversigen Inc.Diversigen, Inc. is a
subsidiary of OraSure Technologies Inc. Diversigen and CoreBiome,
Inc. (also an OraSure subsidiary), came together to create one
company under the Diversigen brand that is powering microbiome
discovery through sequencing, analysis, and
consulting services geared toward the study of the microbiome of
living organisms and environments. Diversigen provides consultative
end-to-end solutions for sequencing, bioinformatics, and
statistical analysis for the study of the microbiome of living
organisms and environments. Diversigen, Inc. operates a
state-of-the-art CLIA accredited laboratory deploying a variety of
techniques to extract high quality nucleic acids from a multitude
of sample types for subsequent metagenomics analysis. Diversigen’s
flexible sequencing and computing capacity, combined with ongoing
improvements in analytic tools and their applications, allows for
customized project-specific strategies. For more information, visit
www.diversigen.com or contact info@diversigen.com.
About OraSure Technologies
OraSure Technologies empowers the global
community to improve health and wellness by providing access to
accurate, essential information. OraSure, together with its
wholly-owned subsidiaries, DNA Genotek, Diversigen, and
Novosanis, provides its customers with end-to-end solutions
that encompass tools, services and diagnostics.
The OraSure family of companies is a leader in the
development, manufacture, and distribution of rapid diagnostic
tests, sample collection and stabilization devices, and molecular
services solutions designed to discover and detect critical medical
conditions. OraSure’s portfolio of products is sold globally to
clinical laboratories, hospitals, physician’s offices, clinics,
public health and community-based organizations, research
institutions, government agencies, pharma, commercial entities and
direct to consumers. For more information, visit
www.orasure.com.
Investor Contact:Sam MartinArgot
Partners212-600-1902orasure@argotpartners.com |
Media Contact:Jeanne MellVP
Corporate Communications484-353-1575media@orasure.com |
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Apr 2024 to May 2024
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From May 2023 to May 2024